NEW YORK, Aug. 29, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced its approval of a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iqlik, for ...
March 25, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that the subcutaneous injection formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback